Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Funding

Approval  ·  Weekly Digest - 20 June to 26 June 2026
European Commission approves Trodelvy for first-line metastatic TNBC

Weekly Digest – June 2026 Weekly Digest – June 2026 23 June 2026: European Commission approves Trodelvy for first-line metastatic TNBC Gilead Sciences has received European Commission approval for Trodelvy as a first-line treatment for adult patients with unresectable locally […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 20 June to 26 June 2026
European Commission approves PADCEV as perioperative treatment for cisplatin-ineligible patients with resectable MIBC

Weekly Digest – June 2026 Weekly Digest – June 2026 24 June 2026: European Commission approves PADCEV as perioperative treatment for cisplatin-ineligible patients with resectable MIBC Astellas and Pfizer have received European Commission approval for PADCEV in combination with KEYTRUDA […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 20 June to 26 June 2026
NMPA accepts Tecotabart Vedotin NDA for third-line CLDN18.2+ Gastric cancer

Weekly Digest – June 2026 Weekly Digest – June 2026 23 June 2026: NMPA accepts Tecotabart Vedotin NDA for third-line CLDN18.2+ Gastric cancer The NDA for LM-302, a CLDN18.2-targeting antibody-drug conjugate developed by Sino Biopharmaceutical, has been accepted by China’s […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 20 June to 26 June 2026
Lonza and InduPro announce licensing agreement to advance next-generation ADC therapeutics

Weekly Digest – June 2026 Weekly Digest – June 2026 22 June 2026: Lonza and InduPro announce licensing agreement to advance next-generation ADC therapeutics Lonza and InduPro have entered into a licensing agreement to advance next-generation antibody-drug conjugate therapeutics, providing […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 13 June to 19 June 2026
Zai Lab’s Zocilurtatug pelitecan receives EMA Orphan Drug Designation for pulmonary Neuroendocrine carcinoma

Weekly Digest – June 2026 Weekly Digest – June 2026 16 June 2026: Zai Lab’s Zocilurtatug pelitecan receives EMA Orphan Drug Designation for pulmonary Neuroendocrine carcinoma Zai Lab has received Orphan Drug Designation from the European Medicines Agency for Zocilurtatug […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 13 June to 19 June 2026
FDA accepts sBLA for Genentech’s Lunsumio and Polivy combination in relapsed/refractory Large B-cell lymphoma

Weekly Digest – June 2026 Weekly Digest – June 2026 17 June 2026: FDA Accepts sBLA for Genentech’s Lunsumio and Polivy combination in relapsed/refractory Large B-cell lymphoma Genentech has announced that the U.S. FDA has accepted a supplemental Biologics License […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 13 June to 19 June 2026
Oncopeptides submits EMA application for Pepaxti label expansion to third-line treatment

Weekly Digest – June 2026 Weekly Digest – June 2026 12 June 2026: Oncopeptides submits EMA application for Pepaxti label expansion to third-line treatment Oncopeptides has submitted a type 2 variation application to the European Medicines Agency seeking to expand […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 13 June to 19 June 2026
Henlius’ HLX43 in combination with Serplulimab phase 2 NSCLC trial approved in Australia

Weekly Digest – June 2026 Weekly Digest – June 2026 17 June 2026: Henlius’ HLX43 in combination with Serplulimab phase 2 NSCLC trial approved in Australia Henlius has received approval from Australia’s Human Research Ethics Committee, with acknowledgment from the […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest - 13 June to 19 June 2026
Akeso’s HER3 ADC AK138D1 in combination with Ivonescimab phase 1/2 Breast cancer trial enrolls first patient

Weekly Digest – June 2026 Weekly Digest – June 2026 15 June 2026: Akeso’s HER3 ADC AK138D1 in combination with Ivonescimab phase 1/2 Breast cancer trial enrolls first patient Akeso has announced the enrollment of the first patient in the […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 13 June to 19 June 2026
Lonza grants Antharis exclusive license to develop dual-payload ADCs for GI cancers

Weekly Digest – June 2026 Weekly Digest – June 2026 15 June 2026: Lonza grants Antharis exclusive license to develop dual-payload ADCs for GI cancers Antharis Therapeutics has entered into an exclusive, target-specific licensing agreement with Lonza to develop next-generation […]

by Sandhya Ramalingam

Continue Reading
« First‹ Previous101112131415161718Next ›Last »
Page 14 of 63


Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id